

Ensight-Al

AI-Enabled ECG Insights for Cardiovascular Disease Diagnosis

May 2023

Founding Members



Rohan Khera, MD, MS

Assistant Professor, Cardiovascular Medicine & Health Informatics

Director, Cardiovascular Data Science Lab at Yale









Veer SanghaComputer Science and Statistics & Data Science at Yale University

Member of Yale Cardiovascular Data Science Lab









Harlan Krumholz, MD, SM

Harold J Hines Professor of Medicine

Founder and Director of Yale Center for Outcomes Research and Evaluation














The Need for Easier and Accessible Cardiovascular Diagnostics




Stakeholder Challenges (Pharma/Healthcare)

1 Fewer Patients Available for Novel Drugs/Therapies


Reduced Uptake of Therapies requiring Expensive Monitoring



ENSIGHT-AI: AI-enhanced detection of heart disease from ECG Images and wearables



12-lead ECG



Wearable ECG



Our Solution: Designing AI to Learn from ECGs What **Previously Required Advanced Cardiac Imaging**

Combined imaging and ECG data





Proprietary Deep Learning Algorithms

Learning Cardiac Imaging Signatures on ECG images & Signals

Identifies and localizes cardiac dysfunction*




12-lead ECG Images



Wearable derived ECGs




Benefits of an ECG Powered Solution




Our Capacity: seamless workflow and broadly accessible approach to complex CVD diagnosis

System-level Screening



Patient-level Screening



Upload or Scan ECG Image

Diagnostic Prediction for Patient



Significant unmet medical need in highly prevalent disease category with active investment

Global CVD Therapeutics

Market by 2026

\$64B

Individuals with Disease in Active

Development Domains

18.5 Million

Percent of Participants without

Timely Diagnosis

70%


Total Addressable Market is Anyone With

(1) ECG in Health Setting

(2) Wearable with ECG



12-month Roadmap for Product Suite: Primed for Exponential Growth






Robust IP portfolio will protect around image-based AI-ECG analysis as an approach



Phased Go-To-Market approach encompasses Pharma partnerships and point-of-care applications for EACH PRODUCT



Competitive Landscape: Overview of Key Competitors









Our Distinguishing Features and Key Advantages

Direct <u>ECG-Image</u> based Inference*

Broad suite of Individual Products
(at par or exceeds competition)

Diverse patient populations

Clinically rigorous and robust models

Global interoperability ● Infinitely scalable ● Versatile deployment

Existing Relationship with Bristol-Myers Squibb



Our current focus: A push to accelerate regulatory approval for SMART-LV product

Target Product: SMART-LV*

ECG Image-Based LV ejection fraction model

- 5% adult prevalence, 7 in 8 undiagnosed
- Active area of therapeutic development

Contract with Prominent Regulatory Consulting Team

Large Independent Validation Studies

Business plan with broader product strategy

*SMartphone-adaptable Artificial Intelligence for PRediction and DeTection of Left Ventricular Systolic Dysfunction



Awards and Successes

Elizabeth-Barrett Connor Award

National award for Scientific Excellence

American Heart Association. Blavatnik Award
\$300K in non-dilutive capital from Yale




Rita Wilson Prize
\$10K Award from Yale





Our Ask

- <u>Partnership</u>: Investors & partners with strong interest in transformative health technology
- Resources: Roadmap for multiple products to market in the next 12 months. Following needed in 12–18 months:
 - Regulatory team
 - Executive and business team
 - Software team



Thank you



The Future of Cardiovascular Diagnostics

 $\underline{contact@ensight-ai.com}$

(573) 818-4471

SMART-LV (Fully functional demo)

